vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and INTERGROUP CORP (INTG). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $17.3M, roughly 1.1× INTERGROUP CORP). INTERGROUP CORP runs the higher net margin — 8.8% vs -0.8%, a 9.6% gap on every dollar of revenue. On growth, INTERGROUP CORP posted the faster year-over-year revenue change (19.8% vs -25.7%). INTERGROUP CORP produced more free cash flow last quarter ($-481.0K vs $-15.8M). Over the past eight quarters, INTERGROUP CORP's revenue compounded faster (7.8% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Intergroup Corp is a diversified holding firm operating two core segments: real estate and hotel operations. It owns, manages and leases commercial and residential properties across the U.S., and runs limited-service hotels for leisure and business travelers.
CTMX vs INTG — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $17.3M |
| Net Profit | $-154.0K | $1.5M |
| Gross Margin | — | — |
| Operating Margin | -6.9% | 11.6% |
| Net Margin | -0.8% | 8.8% |
| Revenue YoY | -25.7% | 19.8% |
| Net Profit YoY | 97.6% | 155.6% |
| EPS (diluted) | — | $0.71 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $17.3M | ||
| Q3 25 | — | $17.9M | ||
| Q2 25 | $18.7M | $16.2M | ||
| Q1 25 | $50.9M | $16.8M | ||
| Q4 24 | $38.1M | $14.4M | ||
| Q3 24 | $33.4M | $16.9M | ||
| Q2 24 | $25.1M | $13.4M | ||
| Q1 24 | $41.5M | $14.9M |
| Q4 25 | — | $1.5M | ||
| Q3 25 | — | $-535.0K | ||
| Q2 25 | $-154.0K | $-2.2M | ||
| Q1 25 | $23.5M | $-578.0K | ||
| Q4 24 | $18.9M | $-2.7M | ||
| Q3 24 | $5.7M | $-398.0K | ||
| Q2 24 | $-6.5M | $-4.9M | ||
| Q1 24 | $13.8M | $-3.2M |
| Q4 25 | — | 11.6% | ||
| Q3 25 | — | 15.3% | ||
| Q2 25 | -6.9% | 8.1% | ||
| Q1 25 | 44.4% | 14.0% | ||
| Q4 24 | 46.4% | 5.9% | ||
| Q3 24 | 12.3% | 18.5% | ||
| Q2 24 | -33.7% | 3.7% | ||
| Q1 24 | 28.1% | 4.8% |
| Q4 25 | — | 8.8% | ||
| Q3 25 | — | -3.0% | ||
| Q2 25 | -0.8% | -13.9% | ||
| Q1 25 | 46.2% | -3.4% | ||
| Q4 24 | 49.6% | -18.9% | ||
| Q3 24 | 17.2% | -2.4% | ||
| Q2 24 | -26.0% | -36.7% | ||
| Q1 24 | 33.3% | -21.3% |
| Q4 25 | — | $0.71 | ||
| Q3 25 | — | $-0.25 | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-0.27 | ||
| Q4 24 | — | $-1.26 | ||
| Q3 24 | — | $-0.18 | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-1.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $7.5M |
| Total DebtLower is stronger | — | $233.2M |
| Stockholders' EquityBook value | $119.9M | $-85.2M |
| Total Assets | $175.1M | $101.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $7.5M | ||
| Q3 25 | — | $6.0M | ||
| Q2 25 | $49.0M | $6.1M | ||
| Q1 25 | $47.6M | $4.8M | ||
| Q4 24 | $38.1M | $15.4M | ||
| Q3 24 | $40.6M | $12.2M | ||
| Q2 24 | $43.2M | $11.6M | ||
| Q1 24 | $36.2M | $19.5M |
| Q4 25 | — | $233.2M | ||
| Q3 25 | — | $237.8M | ||
| Q2 25 | — | $240.5M | ||
| Q1 25 | — | $241.5M | ||
| Q4 24 | — | $227.2M | ||
| Q3 24 | — | $218.1M | ||
| Q2 24 | — | $225.7M | ||
| Q1 24 | — | $225.0M |
| Q4 25 | — | $-85.2M | ||
| Q3 25 | — | $-86.7M | ||
| Q2 25 | $119.9M | $-86.1M | ||
| Q1 25 | $25.0M | $-84.5M | ||
| Q4 24 | $-456.0K | $-83.9M | ||
| Q3 24 | $-23.5M | $-80.9M | ||
| Q2 24 | $-31.2M | $-80.3M | ||
| Q1 24 | $-31.7M | $-76.4M |
| Q4 25 | — | $101.1M | ||
| Q3 25 | — | $102.5M | ||
| Q2 25 | $175.1M | $104.1M | ||
| Q1 25 | $98.5M | $103.2M | ||
| Q4 24 | $120.5M | $110.6M | ||
| Q3 24 | $139.0M | $109.3M | ||
| Q2 24 | $159.2M | $107.8M | ||
| Q1 24 | $184.7M | $119.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $-23.0K |
| Free Cash FlowOCF − Capex | $-15.8M | $-481.0K |
| FCF MarginFCF / Revenue | -84.6% | -2.8% |
| Capex IntensityCapex / Revenue | 0.1% | 2.6% |
| Cash ConversionOCF / Net Profit | — | -0.02× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $739.0K |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-23.0K | ||
| Q3 25 | — | $-296.0K | ||
| Q2 25 | $-15.8M | $5.9M | ||
| Q1 25 | $-21.0M | $-854.0K | ||
| Q4 24 | $-19.9M | $-781.0K | ||
| Q3 24 | $-20.7M | $3.4M | ||
| Q2 24 | $-19.5M | $6.8M | ||
| Q1 24 | $-26.0M | $1.9M |
| Q4 25 | — | $-481.0K | ||
| Q3 25 | — | $-1.3M | ||
| Q2 25 | $-15.8M | $3.6M | ||
| Q1 25 | $-21.2M | $-1.2M | ||
| Q4 24 | $-20.0M | $-1.1M | ||
| Q3 24 | $-20.7M | $3.1M | ||
| Q2 24 | $-19.6M | $2.7M | ||
| Q1 24 | $-26.2M | $1.1M |
| Q4 25 | — | -2.8% | ||
| Q3 25 | — | -7.1% | ||
| Q2 25 | -84.6% | 22.5% | ||
| Q1 25 | -41.6% | -6.8% | ||
| Q4 24 | -52.5% | -7.8% | ||
| Q3 24 | -62.1% | 18.3% | ||
| Q2 24 | -78.2% | 20.4% | ||
| Q1 24 | -63.1% | 7.6% |
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 5.4% | ||
| Q2 25 | 0.1% | 13.9% | ||
| Q1 25 | 0.2% | 1.8% | ||
| Q4 24 | 0.2% | 2.4% | ||
| Q3 24 | 0.1% | 1.6% | ||
| Q2 24 | 0.4% | 30.4% | ||
| Q1 24 | 0.3% | 4.9% |
| Q4 25 | — | -0.02× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
INTG
| Hotel Operations | $12.7M | 73% |
| Real Estate Operation | $4.6M | 27% |
